Phaseline

Companies › Labo'Life

Labo'Life: clinical trials, targets and expected readouts

4 active drug programs in 6 registered trials: 6 Phase 4; Infectious disease; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
2LHERP®
Immune regulator for herpes simplex virus infections
–Phase 4Herpes SimplexMar 2027
2LPAPI®
unclear - likely immunotherapeutic agent for HPV clearance
–Phase 4Human Papilloma VirusOct 2027
2LEBV®
Unclear - composition not specified in registry text
–Phase 4EBV InfectionAug 2028
2LVERU®JUNIOR
Immune regulator for HPV-related warts treatment
–Phase 4Common WartDec 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT040659712LHERP®Phase 4Herpes SimplexInfectious diseaseMar 2027
NCT042329172LPAPI®Phase 4Human Papilloma VirusInfectious diseaseOct 2027
NCT043082782LEBV®Phase 4EBV InfectionInfectious diseaseAug 2028
NCT043082782LEBV®Phase 4EBV InfectionInfectious diseaseAug 2028
NCT039777532LVERU®JUNIORPhase 4Common WartInfectious diseaseDec 2028
NCT039777532LVERU®JUNIORPhase 4Common WartInfectious diseaseDec 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Laboratorio Farmaceutico SIT srl Zero Point Five Therapeutics Lallemand Pharma Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) MicuRx

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.